<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04811274</url>
  </required_header>
  <id_info>
    <org_study_id>APHP201476</org_study_id>
    <secondary_id>2020-A02750-39</secondary_id>
    <nct_id>NCT04811274</nct_id>
  </id_info>
  <brief_title>Macrophages, GM-CSF and MARS Proteinosis</brief_title>
  <acronym>MacroMARS</acronym>
  <official_title>Study of Macrophage Function and of the GM-CSF Signaling Pathway in Alveolar Proteinosis by Mutations of the MARS Gene</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Mutations in the MARS gene encoding methionyl-tRNA synthetase are responsible for a genetic&#xD;
      form of alveolar proteinosis (PAP), but the pathophysiological mechanisms of the respiratory&#xD;
      phenotype are not known.&#xD;
&#xD;
      The main hypothesis is that the PAP phenotype in these patients is secondary to a defective&#xD;
      clearance of the surfactant by the alveolar macrophages.&#xD;
&#xD;
      The main objective of the study is to study the clearance capacity of lipoproteinaceous&#xD;
      material by macrophages of patients with MARS related PAP. This will be investigate in&#xD;
      cultured macrophages derived from peripheral blood monocytes of patients (patients with MARS&#xD;
      related PAP) and controls (patients without MARS related PAP).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Pulmonary alveolar proteinosis (PAP) is a rare respiratory disease characterized by the&#xD;
      accumulation of lipoproteinaceous material within the pulmonary alveoli, resulting in the&#xD;
      majority of cases from a defective clearance of the surfactant by intra-alveolar macrophages.&#xD;
&#xD;
      Mutations in the MARS gene encoding methionyl-tRNA synthetase are responsible for a genetic&#xD;
      form of alveolar proteinosis, but the pathophysiological mechanisms leading to mutations in&#xD;
      the respiratory phenotype are not known.&#xD;
&#xD;
      The main hypothesis is that the alveolar proteinosis phenotype in these patients is secondary&#xD;
      to a defective clearance of the surfactant by the alveolar macrophages.&#xD;
&#xD;
      The main objective of the study is to study the clearance capacity of lipoproteinaceous&#xD;
      material by macrophages of patients with MARS related PAP. This will be investigate in&#xD;
      cultured macrophages derived from peripheral blood monocytes of patients (patients with MARS&#xD;
      related PAP) and controls (patients without MARS related PAP).&#xD;
&#xD;
      The subjects and the controls will be included during a hospitalization during which a blood&#xD;
      sample and a bronchoscopy with broncoalveolar lavage must be performed as part of their care.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 7, 2021</start_date>
  <completion_date type="Anticipated">June 7, 2024</completion_date>
  <primary_completion_date type="Anticipated">June 7, 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Measurement of the clearance</measure>
    <time_frame>Day 0</time_frame>
    <description>Measurement of the clearance of abnormal lipo-proteinaceous material (from patients) at 48h of culture by cultured macrophages derived from peripheral blood monocytes from patients and controls.&#xD;
Microscopic examination of cell samples prepared on slide after cytospin and stained with oil red'O.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Measurement of the clearance after supplementation with methionine</measure>
    <time_frame>Day 0</time_frame>
    <description>Measurement of the clearance of abnormal lipo-proteinaceous material (from patients) at 48h culture with methionine supplementation in culture medium by cultured macrophages derived from peripheral blood monocytes from patients and controls.&#xD;
Microscopic examination of cell samples prepared on slide after cytospin and stained with oil red'O.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cellular phenotyping and study of the GM-CSF pathway</measure>
    <time_frame>Day 0</time_frame>
    <description>Description : Study the impact of mutations on the cell phenotype and the GM-CSF signalling pathway.&#xD;
(i) CD11b and CD49d cell immunostaining which are surface markers of healthy alveolar macrophages ; (ii) measurement of the level of intracellular phosphorylation of STAT5 by flow cytometry; and (iii) measurement of the level of expression of the SPI1, PPARγ and ABCG1 genes by quantitative PCR.&#xD;
These measurements will be performed in cultured macrophages derived from peripheral blood monocytes of patients and controls, but also in alveolar macrophages directly isolated from the BAL fluid of patients and controls. All these measurements will be performed in response to incubation with GM-CSF.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Pulmonary Alveolar Proteinosis (PAP)</condition>
  <condition>MARS</condition>
  <condition>Genetic Mutation</condition>
  <arm_group>
    <arm_group_label>Patients</arm_group_label>
    <description>Minor patients with alveolar proteinosis by mutations of the MARS gene.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Controls</arm_group_label>
    <description>Minors patients without alveolar proteinosis.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Blood collection</intervention_name>
    <description>2 to 5 ml</description>
    <arm_group_label>Controls</arm_group_label>
    <arm_group_label>Patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Bronchoalveolar lavage fluid collection</intervention_name>
    <description>5 to 25 ml</description>
    <arm_group_label>Controls</arm_group_label>
    <arm_group_label>Patients</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Whole blood Bronchoalveolar lavage fluid (BALF)&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Minor patients with alveolar proteinosis by mutations of the MARS gene and minor patients&#xD;
        without alveolar proteinosis, hospitalized for their care at Necker Enfants Malades&#xD;
        hospital and for whom a blood sample and a bronchoscopy with bronchoalveolar lavage must be&#xD;
        performed for their care.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Minors from 0 to 17 years hospitalized for their care at Necker Enfants Malades&#xD;
             hospital and for whom a blood sample and a bronchoscopy with bronchoalveolar lavage&#xD;
             must be performed as part of their care&#xD;
&#xD;
          -  Information and consent of the holders of parental authority and the patient&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        - Refusal of holders of parental authority or patient&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alice HADCHOUEL</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alice HADCHOUEL, MD, PhD</last_name>
    <phone>1 44 49 48 47</phone>
    <phone_ext>+33</phone_ext>
    <email>alice.hadchouel-duverge@aphp.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hélène MOREL</last_name>
    <phone>1 44 38 16 53</phone>
    <phone_ext>+33</phone_ext>
    <email>helene.morel@aphp.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hôpital Necker-Enfants Malades</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alice HADCHOUEL, MD, PhD</last_name>
      <phone>1 44 49 48 47</phone>
      <phone_ext>+33</phone_ext>
      <email>alice.hadchouel-duverge@aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Isabelle SERMET-GAUDELUS, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>March 19, 2021</study_first_submitted>
  <study_first_submitted_qc>March 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 23, 2021</study_first_posted>
  <last_update_submitted>June 26, 2021</last_update_submitted>
  <last_update_submitted_qc>June 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pulmonary alveolar proteinosis (PAP)</keyword>
  <keyword>Mutations in the MARS gene</keyword>
  <keyword>Methionyl-tRNA synthetase</keyword>
  <keyword>Surfactant clearance</keyword>
  <keyword>Alveolar macrophages</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Alveolar Proteinosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

